June 17, 2021
BONESUPPORT receives “breakthrough device designation” for CERAMENT G for the indication trauma
Media
June 17, 2021
Targovax announces completed enrollment in the phase 1/2 trial with ONCOS-102 in combination with durvalumab in patients with advanced colorectal cancer with peritoneal malignancies
June 16, 2021
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
June 14, 2021
Fusion Pharmaceuticals Announces Preliminary Safety And Dosimetry Results From Its Single-Dose Portion Of The Phase 1 Study Of FPI-1434
June 14, 2021
Targovax releases presentations of ONCOS-102 mesothelioma 24-month data
June 11, 2021
Vicore announces FDA acceptance for pivotal phase 3 trial of C21 in COVID-19
June 10, 2021
Targovax’s ONCOS-102 mesothelioma 24-month data shows class-leading median overall survival
June 09, 2021
InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm™ Program, Plans for Pivotal Phase 3 Study and Expansion of Senior Management Team
June 08, 2021
CARISMA Therapeutics Appoints Richard Morris as Chief Financial Officer
June 07, 2021
Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. As Senior Vice President, Research
